This study was designed to evaluate the effectiveness of curcumin supplement as antioxidant and anti-inflammatory in patients with chronic bronchial asthma. Forty patients diagnosed with chronic bronchial asthma were enrolled in this study and allocated into group (1) patients   assigned to receive conventional therapy of asthma, and group (2) patient assigned to receive conventional therapy of asthma combined with 750 mg curcumin supplement twice daily for two months. Pulmonary function test, asthma control test, serum interleukin-6 and serum extracellular super oxide dismutase 3 were measured before and after two months in both study groups. After two months, the mean values of pulmonary function test (spirometry) and asthma control score showed significant increase compared to pre-treatment values in group 2 patients (P<0.01). Moreover, there was marked decrease in the level of interleukin-6 in group 2 patients after two months (p< 0.05) compared to the increased in group 1 patients. The mean level of super oxide dismutase 3 didn’t show any increase in both study groups after treatment. Curcumin supplement produced improvement in pulmonary function of patients with chronic bronchial asthma along with the reduction in inflammatory status. No change in endogenous oxidative status after curcumin supplementation.

Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation together with increased oxidative stress that lead to clinical symptoms of asthma.    Obesity is a known risk factor of asthma as the obesity is correlated with systemic inflammation and airway restriction. Curcumin, a natural product derived from the rhizomes of Curcuma longa (Turmeric), has a wide range of beneficial properties including anti-inflammatory and weight reducing agent. This study was designed to evaluate the effect of curcumin as supplement therapy on the pulmonary function, total and differential white blood cell count and metabolic status of chronic bronchial asthmatic patients. It is a prospective randomized controlled interventional study carried out on 40 patients visiting Al-Yarmouk teaching hospital and conducted from October 2017 to April 2018. The patients were allocated into group1; include 17 asthmatic patients assigned to receive conventional therapy for asthma alone, and group 2; include 23 asthmatic patients assigned to receive conventional therapy for asthma plus 750 mg curcumin capsule twice daily for two months. Results revealed significant improvement in forced expiratory volume in one second (FEV1) and the ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC) in group 2 patients after two months(P<0.01). The total white blood cell count didn’t show any difference after treatment except decrease in neutrophil count after curcumin supplement (p< 0.05). The leptin level and body mass index present with no significant difference in both groups after two months (p >0.05).

Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation together with increased oxidative stress that lead to clinical symptoms of asthma. Obesity is a known risk factor of asthma as the obesity is correlated with systemic inflammation and airway restriction. Curcumin, a natural product derived from the rhizomes of Curcuma longa (Turmeric), has a wide range of beneficial properties including anti-inflammatory and weight reducing agent. This study was designed to evaluate the effect of curcumin as supplement therapy on the pulmonary function, total and differential white blood cell count and metabolic status of chronic bronchial asthmatic patients. It is a prospective randomized controlled interventional study carried out on 40 patients visiting Al-Yarmouk teaching hospital and conducted from October 2017 to April 2018. The patients were allocated into group1; include 17 asthmatic patients assigned to receive conventional therapy for asthma alone, and group 2; include 23 asthmatic patients assigned to receive conventional therapy for asthma plus 750 mg curcumin capsule twice daily for two months. Results revealed significant improvement in forced expiratory volume in one second (FEV1) and the ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC) in group 2 patients after two months(P<0.01). The total white blood cell count didn’t show any difference after treatment except decrease in neutrophil count after curcumin supplement (p< 0.05). The leptin level and body mass index present with no significant difference in both groups after two months (p >0.05).

Introduction: Gestational diabetes mellitus (GDM) is one of the most common medical problems occurred during pregnancy. GDM increase the chance for developing type 2 diabetes meletus by seven times. The overall prevalence of GDM in pregnancy is 1-14% according to the American Diabetes Association. Material and Methods: a self-administered questionnaire was used to collect data. The information was collected from pregnant women with gestational DM to assess some maternal risk factors and compare blood glucose level according to different treatment types for GDM. Results: The present study reported that (40.38%) of GDM patients have advanced age (≥35 yrs.). First pregnancy was a risk factors for GDM and it was reported by (9.62%). History of HT and GDM during prior pregnancies were reported by (11.54%) and (% 34.62) respectively. Hypertension or preeclampsia in the current pregnancy was reported by (3.85%). Positive family history of diabetes was associated with (26.92%) GDM patients. All Patients of the present study reported no previous PCOS and smoking history. Also in this study, 44 patients out of 52 GDM patients use medications to control the glucose intolerance, while other patients control it by diet. There were no statistical differences found between treatment groups in term of blood glucose control. Conclusion: Age, history of GDM in the previous pregnancies and family history of diabetes mellitus were identifiable as a risk factors for GDM and their effect were significant in this study while the effect of other risk factors were non-significant. No statistical differences found between treatment groups in term of blood glucose level control and no group achieved the glycemic target.